Sierra to Present at September Investor Conferences
Sierra Oncology (SRRA) announced that CEO Dr. Stephen Dilly will present at two key investor conferences this September. The H.C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 16 at 11:00 am ET, while the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 21 at 11:40 am ET. The presentations will focus on the development of momelotinib, a JAK inhibitor aimed at treating myelofibrosis. Replays will be available on their corporate website.
- None.
- None.
VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis, today announced that Dr. Stephen Dilly, President and CEO, will present an overview of the company at two investor conferences in September: the H.C. Wainwright 22nd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
H.C. Wainwright Annual Global Investment Conference | |
Date: | Wednesday, Sept 16 |
Time: | 11:00 am ET |
Webcast link: | |
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | |
Date: | Monday, September 21 |
Time: | 11:40 am ET |
Webcast Link: | |
Replays of these presentations will be available on the Investors section of Sierra's corporate website in the Events & Webcast tab.
About Sierra Oncology
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated mechanism of action that enables it to potentially address all three key drivers of myelofibrosis: anemia, constitutional symptoms and enlarged spleen. More than 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.
Sierra has launched MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor. The U.S. Food and Drug Administration has granted Fast Track designation to momelotinib. Momelotinib is protected by patents anticipated to provide potential exclusivity to 2040 in the United States and Europe (inclusive of potential Patent Term Extension or Supplementary Protection Certificate).
For more information, please visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Sierra Oncology's expectations from current data, anticipated clinical development activities, expected timing and success of enrollment of MOMENTUM and potential benefits of momelotinib. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that Sierra Oncology's cash resources may be insufficient to fund its current operating plans and it may be unable to raise additional capital when needed, the risk that disruptions and impacts of COVID-19 will be significant and lengthy, Sierra Oncology may be unable to successfully develop and commercialize momelotinib, momelotinib may not demonstrate safety and efficacy or otherwise produce positive results, Sierra Oncology may experience delays in the clinical development of momelotinib, Sierra Oncology may be unable to acquire additional assets to build a pipeline of additional product candidates, Sierra Oncology's third-party manufacturers may cause its supply of materials to become limited or interrupted or fail to be of satisfactory quantity or quality, Sierra Oncology may be unable to obtain and enforce intellectual property protection for its technologies and momelotinib and the other factors described under the heading "Risk Factors" set forth in Sierra Oncology's filings with the Securities and Exchange Commission from time to time. Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
View original content:http://www.prnewswire.com/news-releases/sierra-to-present-at-september-investor-conferences-301128608.html
SOURCE Sierra Oncology
FAQ
What are the presentation dates for Sierra Oncology (SRRA) in September 2020?
Who will represent Sierra Oncology at the investor conferences?
What is momelotinib and its significance for Sierra Oncology (SRRA)?
What time will Sierra Oncology's presentations take place?
Where can I access the replays of Sierra Oncology's conference presentations?
